Organigram Global Inc. (NASDAQ: OGI)

Organigram Global Inc. is a licensed cannabis cultivator and producer of consumer packaged goods containing cannabis. The company operates in the cannabis industry, focusing on cultivation, production, and distribution of cannabis products. Organigram manufactures and distributes cannabis products to wholesale and retail channels in Canada, exports to international jurisdictions, and distributes hemp-derived tetrahydrocannabinol (THC) beverages and edibles in the U.S.

The company generates revenue through the sale of dried flower and cannabis derivative products, which are sold to recreational cannabis, medical cannabis, wholesale, and international cannabis markets. Organigram's primary products include dried flower, pre-rolls, infused pre-rolls, gummies, beverages, and various extract products. The company's customer base includes recreational and medical cannabis users, as well as international medical cannabis customers in Australia, Germany, and the UK.

• Moncton Campus (Indoor Cultivation and Manufacturing): This 500,000+ square foot state-of-the-art flagship facility features three-tiered, strain-specific grow rooms with controlled environmental factors. The facility's capabilities include extraction, cannabinoid testing, and automated production and packaging lines. The Moncton Campus also houses the Centre of Excellence (CoE) for research on cannabis in collaboration with British American Tobacco p.l.c. (BAT). The facility produces dried cannabis flower, pre-rolls, and infused pre-rolls, with a capacity to produce over 100,000 kg of dried cannabis flower annually. The Moncton Campus is seeking European Union Good Manufacturing Practice (EU-GMP) certification, which would open up business opportunities in international markets.

• Winnipeg Facility (Ingestible Products Manufacturing): This purpose-built, highly automated 51,000 square-foot facility is capable of producing up to 48 million gummies annually. The facility also contains specialized manufacturing equipment for the Company's FAST TM (Fast Acting Soluble Technology) nanoemulsion technology used in some of its ingestible products. The Company's newly commissioned beverage manufacturing line is capable of producing up to 2.6 million beverage cans annually, but is not yet operational.

• Lac-Supérieur Facility (Hash/Concentrates and Premium Flower): This greenhouse facility spans 33,000 square feet and is equipped to produce 2,400 kg of premium flower and over 2 million packaged units of hash annually. The facility also produces craft flower with a staggered cultivation cycle averaging 8 weeks per cycle.

• Aylmer Facility (Extraction and Manufacturing): This facility houses advanced extraction and manufacturing capabilities, including hydrocarbon and CO2 extraction refinement, formulation, post-processing of minor cannabinoids, and infused and regular pre-roll production. The Aylmer Facility processes cannabis flower into various other forms of cannabis such as cannabis extract, cannabis distillate, cannabis isolate and cannabis liquid diamonds, for use in a variety of cannabis products including vapes, gummies and diamonds.

• London Facility (Warehousing and Distribution): This centralized warehouse distribution hub in Ontario, Canada's most populous province, supports growing demand for Organigram's products, optimizes fulfillment, and reduces the cost and complexity of shipping products from the Moncton Campus to Central and Western Canada.

Organigram holds the #1 market share position in the Canadian recreational cannabis market. The company's competitive advantages include its strong innovation pipeline, consumer focus, efficiency, and market expansion strategies. Organigram maintains a diversified brand and product portfolio with competitive pricing that is aligned with evolving consumer preferences. The company's strategic partnership with BAT, its largest institutional shareholder, provides access to resources and expertise for developing next-generation cannabis products.

Organigram serves a diverse international medical cannabis customer base in Australia, Germany, and the UK. The company also participates in the hemp-derived beverages and edibles segments in the U.S. through its acquisition of Collective Project Limited (CPL) and the launch of the "happly" lifestyle edibles brand. Organigram's customer base includes recreational and medical cannabis users, as well as international medical cannabis customers. The company's products cater to various consumption occasions, from accessible value offerings to premium, experience-driven products.